RiMO-301 not checked
Coordination Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of RiMO-301 will be administered via an intratumoral injection. PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity. Patients will receive hypofractionated radiation in 5 fractions.”In the company’s words, NCT05838729 on ClinicalTrials.gov
- Tested for
- Head Neck Cancer, Intratumoral Injection
- Main trialPhase 1/2
- “This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.”In the company’s words, NCT05838729 on ClinicalTrials.gov
- Other names
- Radiotherapy
Other drugs for Head Neck Cancer
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- BupiZengeOncoZenge AB · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- APG-157Aveta Biomics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Sep 2026 | Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer | |
| Phase 1Completed | 16 Jun 2025 | Phase I Study of RiMO-301 With Radiation in Advanced Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026